Amended Current Report Filing (8-k/a)
April 14 2020 - 4:48PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
April 9, 2020
Enzo Biochem, Inc.
(Exact Name of Registrant as Specified in Its
Charter)
New York
(State or Other Jurisdiction of Incorporation)
001-09974
|
13-2866202
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
527 Madison Avenue
|
|
New York, New York
|
10022
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(212) 583-0100
(Registrant’s Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of Each Class
|
Trading Symbol
|
Name of Each Exchange on Which Registered
|
Common Stock, $.01 par value
|
ENZ
|
The New York Stock Exchange
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-1 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
On April 9, 2020, Enzo Biochem,
Inc. (the “Company”) filed with the Securities and Exchange Commission a Current Report on Form 8-K, dated April 9,
2020 (the “Form 8-K”). The Form 8-K inadvertently (i) included Item 7.01 “Regulation FD Disclosure” and
(ii) excluded from Item 8.01 “Other Events” certain disclosures regarding litigation involving the claims of certain
patents held by the Company (the “Patent Litigation Update”). The sole purpose of this Current Report on Form 8-K/A
is to (i) delete Item 7.01 in its entirety from the Form 8-K and (ii) add the Patent Litigation Update to Item 8.01 of the Form
8-K. With the exception of such revisions, no other changes have been made to the Form 8-K, including the disclosure previously
included under Item 8.01 of the Form 8-K.
The Company is also filing this
Current Report on Form 8-K to provide an update regarding litigation involving the claims of certain patents held by the Company.
On March 30, 2020, the U.S. Supreme Court denied the Company’s petition for a writ of certiorari of the U.S. Court of Appeals
for the Federal Circuit’s June 20, 2019 decision that affirmed the U.S. District Court
for the District of Delaware’s ruling that the asserted claims of U.S. Patent Nos. 6,992,180
(the “180 Patent”) and 8,097,405
(the “405 Patent”) are invalid for lack of enablement. The denial of the Company’s
petition pertains to three separate actions: (1) Roche Molecular Systems, Inc.; Roche Diagnostics Corp.; Roche Diagnostics Operations,
Inc.; and Roche Nimblegen, Inc. regarding the 180 Patent; (2) Becton, Dickinson and Co.; Becton Dickinson Diagnostics Inc.; and
GeneOhm Sciences, Inc. regarding the 180 Patent; and (3) Abbott Laboratories and Abbott Molecular, Inc. regarding the 180 Patent
and the 405 Patent.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ENZO BIOCHEM, INC.
|
|
|
|
|
Date: April 14, 2020
|
By:
|
/s/ David Bench
|
|
|
|
David Bench
|
|
|
|
Chief Financial Officer
|
|
|
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2024 to May 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From May 2023 to May 2024